Ocular Therapeutix (OCUL) Receives Analyst Rating

Ocular Therapeutix (OCUL) : The consensus on Ocular Therapeutix (OCUL) based on 3 analyst recommendation on the company stock is 1.17, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future.

Ocular Therapeutix (OCUL) : The highest short term price target forecast on Ocular Therapeutix (OCUL) is $60 and the lowest target price is $16. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $32.33 with a standard deviation of $24.09.


Also, JMP Securities initiates coverage on Ocular Therapeutix (NASDAQ:OCUL).The analysts at the brokerage house have a current rating of Outperform on the shares. The rating by the firm was issued on August 11, 2016.

Ocular Therapeutix (NASDAQ:OCUL): After opening at $6.5, the stock dipped to an intraday low of $6.32 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $6.72 and the buying power remained strong till the end. The stock closed at $6.61 for the day, a gain of 1.54% for the day session. The total traded volume was 465,492. The stocks close on the previous trading day was $6.51.

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Companys bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Companys product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Companys lead product candidates are OTX-DP and OTX-TP.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.